Table 2.
Characteristics of included retrospective studies for complementary meta analysis
| Lead author (year) | Treat line | Therapeutic regimen of TKI | Type of EGFR mutation | Sample size (TKI treatment) | ORR (%) | PFS (months) (95% CI) | OS (months) (95% CI) | Score |
|---|---|---|---|---|---|---|---|---|
| Won (2011) | Mix | Gefitinib 250 mg/d, po | 19del | 61 | 63.9 | 9.3 (7.5 to 11.1) | 17.7 (12.3 to 23.1) | 7 |
| or Erlotinib 150 mg/d, po | 21 L858R | 26 | 61.5 | 6.9 (4.1 to 9.7) | 20.5 (3.8–37.2) | |||
| Lee (2013) | 1 | Gefitinib 250 mg/d, po | 19del | 64 | 87.5 | 12.8 | 24.6 | 9 |
| or Erlotinib 150 mg/d, po | 21 L858R | 80 | 75.3 | 11.4 | 21 | |||
| Jackman (2006) | Mix | Gefitinib 250 mg/d, po | 19del | 22 | 73 | 24 | 38 | 6 |
| or Erlotinib 150 mg/d, po | 21 L858R | 10 | 50 | 10 | 17 | |||
| Yoshida (2007) | Mix | Gefitinib 250 mg/d, po | 19del | 8 | 87.5 | 7.8 (7.6‐NA) | – | 8 |
| 21 L858R | 13 | 92.3 | 6 (2.6 to 7.7) | – | ||||
| Igawa (2014) | Mix | Gefitinib 250 mg/d, po | 19del | 68 | 61.8 | 11.3 (8.0 to 14.6) | 32.2 (22.0 to 42.4) | 8 |
| 21 L858R | 56 | 58.9 | 9 (6.7 to 11.3) | 22.7 (9.4 to 36.0) | ||||
| Takano (2006) | Mix | Gefitinib 250 mg/d, po | 19del | 49 | 86 | 10.5 | 22 | 7 |
| 21 L858R | 36 | 67 | 7.4 | 12 |
19del, exon 19 deletion; CI, confidence interval; EGFR, epidermal growth factor receptor; NA, not available; ORR, objective response rate; OS, overall survival; PFS, progression‐free survival; po, orally; Pro, prospective study; RCT, randomized controlled trial; TKI, tyrosine kinase inhibitor.